Compare Bristol-Myers Squibb Co (BMY) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Yum! Brands, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $58.45 (market cap $116.30B), while Yum! Brands, Inc. trades at $152.75 (market cap $43.60B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.7× Yum! Brands, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | YUM | |
|---|---|---|
Market Cap | $116.30B | $43.60B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $168.16 |
52-Week Low | $42.60 | $138.21 |
Enterprise Value | $152.24B | $54.86B |
Dividend Yield | 4.42% | 1.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
YUM Brands trades at $161.69, down 1.13% today, with a bullish technical signal from moving averages and key resistance at $163. The company reported Q1 2026 EPS of $1.50, beating expectations, while revenue grew to $8.21B in 2025. Recent news includes a Taco Bell health investigation and the $2.7B Pizza Hut sale, which may streamline operations.
YUM's outlook is supported by strong cash flow and margin stability, but high debt and competitive pressures pose risks. Analysts maintain a $174.60 price target with a mixed buy/hold consensus. The stock offers growth potential post-Pizza Hut divestiture, though investor sentiment is cautious amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
